Breaking News, Collaborations & Alliances

GSK, ChemoCentryx Form Drug Discovery Alliance

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and ChemoCentryx, Inc. have entered a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including Traficet-EN in late stage development for the treatment of inflammatory bowel disease (IBD). This collaboration provides GSK access to selected targets from a broad pipeline of chemokine-based therapeutics. The alliance with GSK will...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters